SCHEMBL25276334

SCHEMBL25276334

Cc1cc([N+](=O)[O-])cc(F)c1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
GPR35 Q9HC97 5/20 0.65
KMT2A Q03164 6/20 0.52
HTT P42858 6/20 0.52
MEN1 O00255 5/20 0.52
LMNA P02545 4/20 0.52
MAPT P10636 4/20 0.48
TDP1 Q9NUW8 3/20 0.48
HIF1A Q16665 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TTR P02766 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
MAPK1 P28482 1/20 0.48
RECQL P46063 1/20 0.48
PMP22 Q01453 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137222 0.86 ALDH1A1 (0.57) ALDH1A1GPR35KMT2AHTTMEN1
SCHEMBL655655 0.86 GPR35 (0.77) ALDH1A1GPR35KMT2AHTTMEN1
SCHEMBL69972 0.84 GPR35 (0.69) ALDH1A1GPR35KMT2AHTTMEN1
SCHEMBL28009106 0.82 GPR35 (0.67) ALDH1A1GPR35KMT2AHTTMEN1
SCHEMBL12593937 0.80 ALDH1A1 (0.50) ALDH1A1GPR35KMT2AHTTMEN1
SCHEMBL12326844 0.80 ALDH1A1 (0.50) ALDH1A1GPR35KMT2AHTTMEN1
Dinitro Cresol SCHEMBL20734 0.78 GPR35 (1.00) ALDH1A1GPR35KMT2AHTTMEN1
SCHEMBL12933087 0.78 MEN1 (0.84) ALDH1A1GPR35KMT2AHTTMEN1
SCHEMBL429752 0.78 GPR35 (0.71) ALDH1A1GPR35KMT2AHTTMEN1
Dinitro Cresol SCHEMBL29430312 0.78 GPR35 (1.00) ALDH1A1GPR35KMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4448492-B1 COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER REGLAGENE INC (US) 2026-03-04 EP disclosed
US-12404242-B2 Compositions and methods for making and using small molecules in the treatment of cancer REGLAGENE, INC. (US) 2025-09-02 US disclosed
US-20250109105-A1 COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER REGLAGENE, INC. 2025-04-03 US disclosed
EP-4448492-A1 COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER Reglagene, Inc. (US) 2024-10-23 EP disclosed
WO-2023111996-A1 COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER REGLAGENE HOLDING, INC. (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109105-A1 COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER CD47, RB1, TP53 ALDH1A1 1334/4885GPR35 519/4885KMT2A 700/4885
US-12404242-B2 Compositions and methods for making and using small molecules in the treatment of cancer CD47, RB1, TP53 ALDH1A1 1334/4885GPR35 519/4885KMT2A 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.